Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Интерферон a (ИФН-a) в сравнении с ИФН-a + октреотид в лечении больных высокодифференцированными нейроэндокринными опухолями различных локализаций
Интерферон a (ИФН-a) в сравнении с ИФН-a + октреотид в лечении больных высокодифференцированными нейроэндокринными опухолями различных локализаций
Емельянова Г.С., Кузьминов А.Е., Орел Н.Ф. и др. Интерферон a (ИФН-a) в сравнении с ИФН-a + октреотид в лечении больных высокодифференцированными нейроэндокринными опухолями различных локализаций. Современная Онкология. 2017; 19 (2): 61–65.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
До настоящего времени нет достаточных данных, имеет ли преимущество комбинация аналогов соматостатина (АС) с интерфероном a (ИФН-a) по сравнению с монотерапией АС в лечении больных высокодифференцированными нейроэндокринными опухолями (НЭО). В нашем исследовании мы сравниваем токсичность и эффективность монотерапии АС и в сочетании с ИФН-a у больных высокодифференцированными НЭО различных локализаций. Выявлена тенденция к увеличению медианы времени до прогрессирования у больных с НЭО легких по сравнению с больными с НЭО желудочно-кишечного тракта и поджелудочной железы. Токсичность значимо не различалась.
Ключевые слова: нейроэндокринные опухоли, интерферон a.
Key words: neuroendocrine tumors, interferon a.
Ключевые слова: нейроэндокринные опухоли, интерферон a.
________________________________________________
Key words: neuroendocrine tumors, interferon a.
Полный текст
Список литературы
1. Hofland LJ, de Herder WW, Lamberts SWJ. Mechanism of action of somatostatin and interferon in gastroenteropancreatic tumours. In The expanding role of octreotide I: advances in oncology. SWJ Lamberts & Dogliotti (eds.) 2002; p. 89–102.
2. Funa К, Alm GV, Rönnblom L, Oberg K. Evaluation of the natural killer cell-interferon system in patients with mid-gut carcinoid tumours treated with leucocyte interferon. Clin Exp Immunol 1983; 53 (3): 716–24.
3. Aparicio-Pagés MN, Verspaget HW, Peña AS et al. Natural killer cell activity in patients with neuroendocrine tumours of the gastrointestinal tract; relation with circulating gastrointestinal hormones. Neuropeptides 1991; 20 (1): 1–7.
4. Rosewicz S, Detjen K, Scholz A, von Marschall Z. Interferon-alpha: regulatory effects on cell cycle and angiogenesis. Neuroendocrinology; 2004: 80 (1): 85–93.
5. Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol 2001; 12 (S1): 111–4.
6. Eriksson В, Oberg K. Interferon therapy of malignant endocrine pancreatic tumors. Endocrine Tumors of the Pancreas: Recent Advanced in Research and Management, 1995; p. 451–60.
7. Oberg K. Interferon in the management of neuroendocrine GEP_tumors. Digest 2000; 62 (Suppl. 1): 92–7.
8. Arnold R, Rinke A, Klose KJ et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol 2005; 3 (8): 761–71.
9. Kolby L, Persson G, Franzen S, Ahren B. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg 2003; 90: 687–93.
10. Yao J, Guthrie K, Moran C et al. SWOG S0518: Phase III prospective randomized comparison of depot octreotide plus interferon alpha‐2b versus depot octreotide plus bevacizumab (NSC #704865) in advanced, poor prognosis carcinoid patients (NCT00569127). J Clin Oncol 2015; 33 (Suppl.; abstr 4004).
11. Travis WD, Brambilla E, Müller-Hermelink HK et al (eds.). Pathology & Genetics tumours of the lung, pleura, thymus and heart. Lyon: IARC Press, 2004.
12. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97: 934–59.
13. Yao JC, Hassan M, Phan A et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063–72.
14. Surveillance, Epidemiology, and End Results Program: Lung Cancer histologically confirmed SEER 18 registries research data plus Hurricane Katrina impacted Louisiana cases 1973–2010, November 2012.
15. Sakurai H, Asamura H. Large-cell neuroendocrine carcinoma of the lung: surgical management. Thorac Surg Clin 2014; 24: 305–11.
16. Oberg K, Hellman P, Kwekkeboom D et al. Neuroendocrine bronchial and thymic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl. 5): v220–2.
17. Fink G, Krelbaum T, Yellin A et al. Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest 2001; 119: 1647–51.
18. Filosso PL, Oliaro A, Ruffini E et al. Outcome and prognostic factors in bronchial carcinoids: a single-center experience. J Thorac Oncol 2013; 8: 1282–8.
2. Funa К, Alm GV, Rönnblom L, Oberg K. Evaluation of the natural killer cell-interferon system in patients with mid-gut carcinoid tumours treated with leucocyte interferon. Clin Exp Immunol 1983; 53 (3): 716–24.
3. Aparicio-Pagés MN, Verspaget HW, Peña AS et al. Natural killer cell activity in patients with neuroendocrine tumours of the gastrointestinal tract; relation with circulating gastrointestinal hormones. Neuropeptides 1991; 20 (1): 1–7.
4. Rosewicz S, Detjen K, Scholz A, von Marschall Z. Interferon-alpha: regulatory effects on cell cycle and angiogenesis. Neuroendocrinology; 2004: 80 (1): 85–93.
5. Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol 2001; 12 (S1): 111–4.
6. Eriksson В, Oberg K. Interferon therapy of malignant endocrine pancreatic tumors. Endocrine Tumors of the Pancreas: Recent Advanced in Research and Management, 1995; p. 451–60.
7. Oberg K. Interferon in the management of neuroendocrine GEP_tumors. Digest 2000; 62 (Suppl. 1): 92–7.
8. Arnold R, Rinke A, Klose KJ et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol 2005; 3 (8): 761–71.
9. Kolby L, Persson G, Franzen S, Ahren B. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg 2003; 90: 687–93.
10. Yao J, Guthrie K, Moran C et al. SWOG S0518: Phase III prospective randomized comparison of depot octreotide plus interferon alpha‐2b versus depot octreotide plus bevacizumab (NSC #704865) in advanced, poor prognosis carcinoid patients (NCT00569127). J Clin Oncol 2015; 33 (Suppl.; abstr 4004).
11. Travis WD, Brambilla E, Müller-Hermelink HK et al (eds.). Pathology & Genetics tumours of the lung, pleura, thymus and heart. Lyon: IARC Press, 2004.
12. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97: 934–59.
13. Yao JC, Hassan M, Phan A et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063–72.
14. Surveillance, Epidemiology, and End Results Program: Lung Cancer histologically confirmed SEER 18 registries research data plus Hurricane Katrina impacted Louisiana cases 1973–2010, November 2012.
15. Sakurai H, Asamura H. Large-cell neuroendocrine carcinoma of the lung: surgical management. Thorac Surg Clin 2014; 24: 305–11.
16. Oberg K, Hellman P, Kwekkeboom D et al. Neuroendocrine bronchial and thymic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl. 5): v220–2.
17. Fink G, Krelbaum T, Yellin A et al. Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest 2001; 119: 1647–51.
18. Filosso PL, Oliaro A, Ruffini E et al. Outcome and prognostic factors in bronchial carcinoids: a single-center experience. J Thorac Oncol 2013; 8: 1282–8.
2. Funa К, Alm GV, Rönnblom L, Oberg K. Evaluation of the natural killer cell-interferon system in patients with mid-gut carcinoid tumours treated with leucocyte interferon. Clin Exp Immunol 1983; 53 (3): 716–24.
3. Aparicio-Pagés MN, Verspaget HW, Peña AS et al. Natural killer cell activity in patients with neuroendocrine tumours of the gastrointestinal tract; relation with circulating gastrointestinal hormones. Neuropeptides 1991; 20 (1): 1–7.
4. Rosewicz S, Detjen K, Scholz A, von Marschall Z. Interferon-alpha: regulatory effects on cell cycle and angiogenesis. Neuroendocrinology; 2004: 80 (1): 85–93.
5. Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol 2001; 12 (S1): 111–4.
6. Eriksson В, Oberg K. Interferon therapy of malignant endocrine pancreatic tumors. Endocrine Tumors of the Pancreas: Recent Advanced in Research and Management, 1995; p. 451–60.
7. Oberg K. Interferon in the management of neuroendocrine GEP_tumors. Digest 2000; 62 (Suppl. 1): 92–7.
8. Arnold R, Rinke A, Klose KJ et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol 2005; 3 (8): 761–71.
9. Kolby L, Persson G, Franzen S, Ahren B. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg 2003; 90: 687–93.
10. Yao J, Guthrie K, Moran C et al. SWOG S0518: Phase III prospective randomized comparison of depot octreotide plus interferon alpha‐2b versus depot octreotide plus bevacizumab (NSC #704865) in advanced, poor prognosis carcinoid patients (NCT00569127). J Clin Oncol 2015; 33 (Suppl.; abstr 4004).
11. Travis WD, Brambilla E, Müller-Hermelink HK et al (eds.). Pathology & Genetics tumours of the lung, pleura, thymus and heart. Lyon: IARC Press, 2004.
12. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97: 934–59.
13. Yao JC, Hassan M, Phan A et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063–72.
14. Surveillance, Epidemiology, and End Results Program: Lung Cancer histologically confirmed SEER 18 registries research data plus Hurricane Katrina impacted Louisiana cases 1973–2010, November 2012.
15. Sakurai H, Asamura H. Large-cell neuroendocrine carcinoma of the lung: surgical management. Thorac Surg Clin 2014; 24: 305–11.
16. Oberg K, Hellman P, Kwekkeboom D et al. Neuroendocrine bronchial and thymic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl. 5): v220–2.
17. Fink G, Krelbaum T, Yellin A et al. Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest 2001; 119: 1647–51.
18. Filosso PL, Oliaro A, Ruffini E et al. Outcome and prognostic factors in bronchial carcinoids: a single-center experience. J Thorac Oncol 2013; 8: 1282–8.
________________________________________________
2. Funa К, Alm GV, Rönnblom L, Oberg K. Evaluation of the natural killer cell-interferon system in patients with mid-gut carcinoid tumours treated with leucocyte interferon. Clin Exp Immunol 1983; 53 (3): 716–24.
3. Aparicio-Pagés MN, Verspaget HW, Peña AS et al. Natural killer cell activity in patients with neuroendocrine tumours of the gastrointestinal tract; relation with circulating gastrointestinal hormones. Neuropeptides 1991; 20 (1): 1–7.
4. Rosewicz S, Detjen K, Scholz A, von Marschall Z. Interferon-alpha: regulatory effects on cell cycle and angiogenesis. Neuroendocrinology; 2004: 80 (1): 85–93.
5. Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol 2001; 12 (S1): 111–4.
6. Eriksson В, Oberg K. Interferon therapy of malignant endocrine pancreatic tumors. Endocrine Tumors of the Pancreas: Recent Advanced in Research and Management, 1995; p. 451–60.
7. Oberg K. Interferon in the management of neuroendocrine GEP_tumors. Digest 2000; 62 (Suppl. 1): 92–7.
8. Arnold R, Rinke A, Klose KJ et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol 2005; 3 (8): 761–71.
9. Kolby L, Persson G, Franzen S, Ahren B. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg 2003; 90: 687–93.
10. Yao J, Guthrie K, Moran C et al. SWOG S0518: Phase III prospective randomized comparison of depot octreotide plus interferon alpha‐2b versus depot octreotide plus bevacizumab (NSC #704865) in advanced, poor prognosis carcinoid patients (NCT00569127). J Clin Oncol 2015; 33 (Suppl.; abstr 4004).
11. Travis WD, Brambilla E, Müller-Hermelink HK et al (eds.). Pathology & Genetics tumours of the lung, pleura, thymus and heart. Lyon: IARC Press, 2004.
12. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97: 934–59.
13. Yao JC, Hassan M, Phan A et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063–72.
14. Surveillance, Epidemiology, and End Results Program: Lung Cancer histologically confirmed SEER 18 registries research data plus Hurricane Katrina impacted Louisiana cases 1973–2010, November 2012.
15. Sakurai H, Asamura H. Large-cell neuroendocrine carcinoma of the lung: surgical management. Thorac Surg Clin 2014; 24: 305–11.
16. Oberg K, Hellman P, Kwekkeboom D et al. Neuroendocrine bronchial and thymic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl. 5): v220–2.
17. Fink G, Krelbaum T, Yellin A et al. Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest 2001; 119: 1647–51.
18. Filosso PL, Oliaro A, Ruffini E et al. Outcome and prognostic factors in bronchial carcinoids: a single-center experience. J Thorac Oncol 2013; 8: 1282–8.
Авторы
Г.С.Емельянова*1, А.Е.Кузьминов2, Н.Ф.Орел2,3, А.А.Маркович2, А.А.Кузнецова2, В.А.Горбунова2
1 ФГБОУ ВО «Московский медико-стоматологический университет им. А.И.Евдокимова» Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1;
2 ФГБУ «Российский онкологический научный центр им. Н.Н.Блохина» Минздрава России. 115478, Россия, Москва, Каширское ш., д. 23;
3 ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России. 125993, Россия, Москва, ул. Баррикадная, д. 2/1
*docgalina@mail.ru
1 A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation. 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1;
2 N.N.Blokhin Russian Cancer Reseach Center of the Ministry of Health of the Russian Federation. 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23;
3 Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation. 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1
*docgalina@mail.ru
1 ФГБОУ ВО «Московский медико-стоматологический университет им. А.И.Евдокимова» Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1;
2 ФГБУ «Российский онкологический научный центр им. Н.Н.Блохина» Минздрава России. 115478, Россия, Москва, Каширское ш., д. 23;
3 ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России. 125993, Россия, Москва, ул. Баррикадная, д. 2/1
*docgalina@mail.ru
________________________________________________
1 A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation. 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1;
2 N.N.Blokhin Russian Cancer Reseach Center of the Ministry of Health of the Russian Federation. 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23;
3 Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation. 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1
*docgalina@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.